Convalescent Plasma Therapy in Late-State, Severe COVID-19 Infection

被引:4
作者
Kumar, Neil R. [1 ]
Karanam, Veena C. [2 ]
Kumar, Shari [3 ]
Kumar, Sunil D. [4 ,5 ]
机构
[1] Univ Miami, Jackson Mem Hosp, Internal Med, Miami, FL 33136 USA
[2] Univ Miami, Miller Sch Med, Miami, FL USA
[3] Columbia Univ, Coll Dent Med, New York, NY USA
[4] Broward Hlth Med Ctr, Pulm Crit Care, Ft Lauderdale, FL 33316 USA
[5] Broward Hlth Med Ctr, 1600 S Andrews Ave, Ft Lauderdale, FL 33316 USA
关键词
convalescent plasma; COVID-19; severe; late stage; life threatening;
D O I
10.14423/SMJ.0000000000001546
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectivesCurrent evidence favors plasma to be effective against coronavirus disease 2019 (COVID-19) in critically ill patients in the early stages of infection. We investigated the safety and efficacy of convalescent plasma in specifically late-stage (designated as after 2 weeks of hospital admission) severe COVID-19 infection. We also conducted a literature review on the late-stage use of plasma in COVID-19.MethodsThis case series examined eight COVID-19 patients admitted to the intensive care unit (ICU) who met criteria for severe or life-threatening complications. Each patient received one dose (200 mL) of plasma. Clinical information was gathered in intervals of 1 day pretransfusion and 1 hour, 3 days, and 7 days posttransfusion. The primary outcome was effectiveness of plasma transfusion, measured by clinical improvement, laboratory parameters, and all-cause mortality.ResultsEight ICU patients received plasma late in the course of COVID-19 infection, on average at 16.13 days postadmission. On the day before transfusion, the averaged initial Sequential Organ Failure Assessment (SOFA) score, PaO2:FiO(2) ratio, Glasgow Coma Scale (GCS), and lymphocyte count were 6.5, 228.03, 8.63, and 1.19, respectively. Three days after plasma treatment, the group averages for the SOFA score (4.86), PaO2:FiO(2) ratio (302.73), GCS (9.29), and lymphocyte count (1.75) improved. Although the mean GCS improved to 10.14 by posttransfusion day 7, the other means marginally worsened with an SOFA score of 5.43, a PaO2:FiO(2) ratio of 280.44, and a lymphocyte count of 1.71. Clinical improvement was noted in six patients who were discharged from the ICU.ConclusionsThis case series provides evidence that convalescent plasma may be safe and effective in late-stage, severe COVID-19 infection. Results showed clinical improvement posttransfusion as well as decreased all-cause mortality in comparison to pretransfusion predicted mortality. Randomized controlled trials are needed to conclusively determine benefits, dosage, and timing of treatment.
引用
收藏
页码:427 / 433
页数:7
相关论文
共 50 条
[41]   Effect of convalescent plasma as complementary treatment in patients with moderate COVID-19 infection [J].
Baldeon, Manuel E. ;
Maldonado, Augusto ;
Ochoa-Andrade, Miguel ;
Largo, Carolina ;
Pesantez, Monica ;
Herdoiza, Marco ;
Granja, Gerardo ;
Bonifaz, Marco ;
Espejo, Hugo ;
Mora, Francisco ;
Abril-Lopez, Patricio ;
Robles Armijo, Lady Karen ;
Pacheco, Veronica ;
Salazar, Rafael ;
Reinthaller, Steffy ;
Zertuche, Federico ;
Fornasini, Marco .
TRANSFUSION MEDICINE, 2022, 32 (02) :153-161
[42]   Comparison of safety and efficacy of convalescent plasma with fresh frozen plasma in severe covid-19 patients [J].
Bajpai, Meenu ;
Maheshwari, Ashish ;
Kumar, Suresh ;
Chhabra, Karan ;
Kale, Pratibha ;
Narayanan, Ashad ;
Gupta, Amita ;
Gupta, Ekta ;
Trehanpati, Nirupama ;
Agarwal, Reshu ;
Gupta, Kamini ;
Bhardwaj, Ankit ;
Islam, Mojahidul ;
Singh, Ravinder ;
Yadav, Pushpa ;
Kumar, Guresh ;
Sarin, Shiv K. .
ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS, 2022, 94 (04)
[43]   Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy [J].
Casadevall, Arturo ;
Joyner, Michael J. ;
Pirofski, Liise-Anne ;
Senefeld, Jonathon W. ;
Shoham, Shmuel ;
Sullivan, David ;
Paneth, Nigel ;
Focosi, Daniele .
EXPERT REVIEW OF RESPIRATORY MEDICINE, 2023, 17 (05) :381-395
[44]   Combination of convalescent plasma therapy and repurposed drugs to treat severe COVID-19 patient with multimorbidity [J].
Das, Santa Kumar ;
Ranabhat, Kamal ;
Bhattarai, Suraj ;
Karki, Khem Bahadur ;
Gyanwali, Pradip ;
Paneru, Hem Raj ;
Nepal, Bipin ;
Dumre, Shyam Prakash ;
Acharya, Subhash Prasad .
CLINICAL CASE REPORTS, 2021, 9 (04) :2132-2137
[45]   Early high-titer convalescent plasma therapy in patients with moderate and severe COVID-19 [J].
Fazeli, Alieh ;
Sharifi, Shahin ;
Behdad, Fatemeh ;
Okati, Shamsi ;
Esmaielifar, Gilda ;
Jelveh, Nooshin ;
Eshghi, Peyman ;
Mohammadi, Saeed .
TRANSFUSION AND APHERESIS SCIENCE, 2022, 61 (02)
[46]   A matched cohort study of convalescent plasma therapy for COVID-19 [J].
Sostin, Oleg V. ;
Rajapakse, Pramuditha ;
Cruser, Brigid ;
Wakefield, Dorothy ;
Cruser, Daniel ;
Petrini, Joann .
JOURNAL OF CLINICAL APHERESIS, 2021, 36 (04) :523-532
[47]   CONVALESCENT PLASMA THERAPY: A PROMISING APPROACH IN THE TREATMENT OF COVID-19 [J].
Ahire, Eknath D. ;
Sonawane, Vijayraj N. ;
Surana, Khemchand R. ;
Jadhav, Khanderao R. ;
Sonawane, Deepak D. ;
Shah, Ayaz A. .
INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2020, 11 (09) :4078-4086
[48]   Perplexing issues for convalescent immune plasma therapy in COVID-19 [J].
Ozdemir, Oner .
NORTHERN CLINICS OF ISTANBUL, 2021, 8 (06) :634-643
[49]   Convalescent plasma in COVID-19: renewed focus on the timing and effectiveness of an old therapy [J].
Nashaat, Hebat-Allah Hassan ;
Anani, Maha ;
Attia, Fadia M. .
BLOOD RESEARCH, 2022, 57 (01) :6-12
[50]   COVID-19 convalescent plasma therapy through the lens of the third year of the pandemic [J].
Pirofski, Liise-anne .
CLINICAL MICROBIOLOGY AND INFECTION, 2023, 29 (02) :130-132